ContractSorrento Therapeutics, Inc. • June 4th, 2021 • Biological products, (no disgnostic substances)
Party A and Party B, intending to be legally bound, hereby enter into this Contract through full negotiation on the basis of mutual consensus previously achieved with respect to the loan amounts shown below arising out of Party B’s payment of funds on Party A’s behalf as at the end of 2017 in accordance with the provisions of the Contract Law of the People’s Republic of China and other applicable laws, regulations and rules.
EARN-OUT AGREEMENTPaying Agent Agreement • June 4th, 2021 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS EARN-OUT AGREEMENT, dated as of June 1, 2021 (this “Agreement”), is entered into by and among Sorrento Therapeutics, Inc., a Delaware corporation (“Parent”), and Fortis Advisors LLC, a Delaware limited liability company, as representative of the Holders (as defined in Section 1.1) (the “Shareholders’ Representative” and each of Parent and the Shareholders’ Representative a “Party” and together, the “Parties”).
Loan AgreementLoan Agreement • June 4th, 2021 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances)
Whereas, the Borrower desires to apply to the Lender for a loan due to operational demand, and the Lender agrees to grant the Borrower a loan. The Borrower and the Lender, intending to be legally bound, hereby enter into the following terms and conditions under this Contract through mutual negotiation.
